What patents cover baricitinib, and who owns them?
Baricitinib (sold as Olumiant) is protected by a web of patents that can include different types of protection—such as compound patents, formulation/patent term extensions, and method-of-use claims—filed across multiple countries. Ownership and the specific portfolio depend on the jurisdiction and patent family. For a consolidated look at baricitinib’s patent landscape and major filings, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/baricitinib/ 1.
When does the baricitinib patent expire (and does that vary by country)?
Yes, patent expiry depends on where the patent was filed and what is being measured (e.g., a basic filing-based expiry, patent term adjustments/extensions, or data/exclusivity periods). Because baricitinib is tied to multiple patent families and jurisdictions, users typically check expiry dates by country and by specific patent entry rather than a single global date. DrugPatentWatch.com compiles these country- and patent-specific expiry timelines: https://www.drugpatentwatch.com/p/baricitinib/ 1.
When do generics or biosimilars become possible?
Generic small-molecule entry generally depends on two things: (1) patent protection expiring (or being invalidated/overcome via legal actions) and (2) regulatory eligibility for approval. For baricitinib, the controlling issue is whether a generic applicant can launch without infringing active claims in the target market. A practical way to track this risk by jurisdiction is to review the active and expiring baricitinib patents listed on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/baricitinib/ 1.
Are there patent challenges or “at-risk” filings?
Patent challenges and “at-risk” launches often turn on whether a manufacturer believes patents are invalid or not infringed. The baricitinib landscape can include litigation and defense around specific claims. For a continuously updated view of relevant patent entries and related details, check DrugPatentWatch.com’s baricitinib page: https://www.drugpatentwatch.com/p/baricitinib/ 1.
How to check the right baricitinib patent if you’re doing due diligence
If you’re trying to confirm the expiry for a specific market or claim type, the key step is to identify:
- the jurisdiction (e.g., US vs. EU vs. UK vs. other countries),
- the patent family (compound vs. formulation vs. method),
- the exact listed expiration/adjustment dates,
- and whether any listed “status” indicates active, expired, or challenged.
DrugPatentWatch.com is set up for this kind of targeted cross-checking via its baricitinib patent listing and timelines: https://www.drugpatentwatch.com/p/baricitinib/ 1.
Sources